Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, ...

The decision gives certain patients whose cancer has resisted BCG therapy another treatment option aimed at preserving the ...

A retrospective study of 126 bladder cancer patients suggests that ERAS-based perioperative nursing care is associated with ...

A large survey study finds that most bladder cancer patients who undergo cystectomy with urinary diversion continue to face ...

FDA expands Anktiva approval for BCG-unresponsive bladder cancer. Learn about the 62% trial response, eligible patients, ...

A drug that helps the immune system find cancer cells also helps patients avoid having their bladders surgically removed (cystectomy), a new study shows. The findings apply to serious cases after ...

The FDA extended Anktiva to high-grade papillary-only bladder cancer that no longer responds to BCG. Its reasoning rests on a ...

Stage 1 bladder cancer involves lamina propria invasion without detrusor involvement, requiring both eradication of index lesions and mitigation of field-change–driven multifocal recurrence risk.

Researchers at The University of Texas MD Anderson Cancer Center have developed a spatial map of muscle-invasive bladder cancer, revealing how tumor cell states, immune environments and therapeutic ...

Bladder cancer arises from the lining of the bladder, the organ that stores urine, and is one of the most common cancers in the United States. Most patients are diagnosed at an early stage called ...